Free Trial

Amneal Pharmaceuticals (AMRX) Competitors

Amneal Pharmaceuticals logo
$8.24 -0.02 (-0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$8.24 +0.00 (+0.06%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMRX vs. BBIO, VRNA, BPMC, ROIV, ELAN, RGC, LEGN, RVMD, GRFS, and TGTX

Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Legend Biotech (LEGN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

Amneal Pharmaceuticals vs. Its Competitors

BridgeBio Pharma (NASDAQ:BBIO) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

BridgeBio Pharma currently has a consensus target price of $61.20, indicating a potential upside of 30.94%. Amneal Pharmaceuticals has a consensus target price of $11.60, indicating a potential upside of 40.78%. Given Amneal Pharmaceuticals' higher possible upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
3.00
Amneal Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, BridgeBio Pharma had 23 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 25 mentions for BridgeBio Pharma and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.95 beat BridgeBio Pharma's score of 0.64 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
8 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Amneal Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of -0.46% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-524.25% N/A -94.43%
Amneal Pharmaceuticals -0.46%-188.26%5.34%

Amneal Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$221.90M40.00-$535.76M-$3.53-13.24
Amneal Pharmaceuticals$2.79B0.92-$116.89M-$0.04-206.00

BridgeBio Pharma has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Summary

Amneal Pharmaceuticals beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMRX vs. The Competition

MetricAmneal PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.58B$2.44B$5.50B$9.39B
Dividend YieldN/A1.79%4.25%4.09%
P/E Ratio-205.959.1828.1019.86
Price / Sales0.92470.43402.2879.25
Price / Cash5.95160.6835.5357.53
Price / Book-23.544.748.265.72
Net Income-$116.89M$30.99M$3.24B$257.80M
7 Day Performance-1.79%1.00%0.50%1.06%
1 Month Performance4.30%10.07%7.99%11.30%
1 Year Performance10.90%-3.63%28.68%17.00%

Amneal Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMRX
Amneal Pharmaceuticals
2.8574 of 5 stars
$8.24
-0.2%
$11.60
+40.8%
+8.7%$2.58B$2.79B-205.958,100
BBIO
BridgeBio Pharma
4.6415 of 5 stars
$47.69
+2.6%
$61.20
+28.3%
+61.0%$9.06B$221.90M-13.51400Analyst Forecast
Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.3057 of 5 stars
$104.67
-0.2%
$109.00
+4.1%
+370.5%$8.91B$42.28M-52.3430Analyst Forecast
High Trading Volume
BPMC
Blueprint Medicines
1.1282 of 5 stars
$129.36
+0.0%
$128.25
-0.9%
+7.3%$8.35B$508.82M-52.37640Positive News
High Trading Volume
ROIV
Roivant Sciences
2.6493 of 5 stars
$11.63
+2.4%
$16.50
+41.9%
-0.6%$7.91B$29.05M-46.52860Positive News
ELAN
Elanco Animal Health
1.5736 of 5 stars
$14.88
-0.2%
$15.33
+3.1%
+9.5%$7.39B$4.44B20.109,000Analyst Upgrade
Gap Up
RGC
Regencell Bioscience
0.3346 of 5 stars
$14.68
-0.5%
N/AN/A$7.29BN/A0.0010Positive News
Gap Up
LEGN
Legend Biotech
3.6478 of 5 stars
$39.44
+1.2%
$72.70
+84.3%
-28.9%$7.25B$627.24M-66.852,609News Coverage
Positive News
Analyst Forecast
Gap Up
RVMD
Revolution Medicines
4.5405 of 5 stars
$38.37
+0.9%
$68.00
+77.2%
-17.9%$7.15B$11.58M-9.59250Analyst Forecast
GRFS
Grifols
3.5421 of 5 stars
$9.72
-0.2%
$10.30
+6.0%
+23.8%$6.68B$7.81B8.3123,822Gap Up
TGTX
TG Therapeutics
3.395 of 5 stars
$38.92
+5.0%
$43.80
+12.5%
+72.5%$6.18B$329M162.17290

Related Companies and Tools


This page (NASDAQ:AMRX) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners